AnnouncementMar 2026
Mar 2026 · Announcement under Regulation 30 (LODR)-Newspaper Publication 27 Jun - Newspaper Advertisement for Financial Results quarter and year ended March 31, 2026
Source: Bse
Vikas Lifecare Limited (VIKASLIFE)
Small CapPharma stocks · Small cap · NSE
Vikas Lifecare Limited operates in the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 21 Oct, 03:31 pm ISTDetails
Quote21 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result03 May, 02:04 am IST
Score21 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
51Neutralfull bear SMA stack · SMA20 -4.3% / mo · MACD − · near 52W low · sector +4.9pp vs Nifty 500 (3M)
Stock trend: 18
Sector RS: 100
Sector 3M: -0.7% vs Nifty 500 -5.6%
Pharma FPI tailwindNot confirmed
Latest mapped FPI equity flow was not positive. View sector evidence
Technical chart
VIKASLIFED candles · FIT view-26.4%Latest close ₹1.17 on 2026-10-21
Bar
+0.0%
RSI
38
MACD hist
-0.00
52W pos
11%
2026-10-21O ₹1.17H ₹1.20L ₹1.17C ₹1.17Vol 15.7L sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
VIKASLIFENifty PharmaNifty 500
- VIKASLIFE
- -11.4%
- Nifty 500
- -6.5%
- Nifty Pharma
- -2.0%
- Vs Nifty 500
- -4.9 pp
Chart stats
21 Oct 2026- From 52W high
- -45.8%
- 52W range position
- 11%
- ATR (14)
- 2.9%
- Volume vs 20D
- 0.80x
- Avg traded value
- ₹0.2 Cr
- 20D price channel
- ₹1.2 - ₹1.3
₹2.2
₹1.1 - ₹2.2
₹0
Latest completed session
20-session average
20.1% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Verify management risk first
Do not let cheap valuation override weak Trust or governance evidence.
U-Score
Legacy · FAIR VALUE51
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Good55
Revenue +25.2% · PAT NDF YoY
Technical
Neutral51
Price trend and sector-relative-strength timing.
Valuation
Legacy model+74.0%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence44
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Good · 55/100Rev +25% YoY · margin expansion · +74% QoQ
Filed 21 Apr 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹169 Cr | +25.2% | +74.2% |
| EBITDA | ₹-26 Cr | -13.0% | +13.3% |
| Operating margin | -16.0% | +100 bps | +1500 bps |
| PAT | ₹42 Cr | NDF | NDF |
| PAT margin | 24.9% | +2707 bps | +5475 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 12.20
- P/B
- 0.41
- EV/EBITDA
- —
- Market Cap
- 225.00Cr
Profitability
- ROE
- 3.40%
- ROCE
- 2.16%
- ROA
- 2.37%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 46.00%
- EPS 5Y
- 50.00%
- Revenue 3Y
- 2.00%
- EPS 3Y
- 47.00%
Balance Sheet
- Debt/Equity
- 0.19
- Interest Coverage
- -16.57×
- Altman Z
- 1.74
- Book Value
- 2.97
Cash Flow
- FCF Yield
- —
- FCF Positive Y
- 1/5
- OCF
- 310.00 Cr
- EPS TTM
- 0.10
Shareholding
- Promoter Hold
- 14.20%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 14%
Financial History
Updated 21/10/2026
Revenue
₹ CrLatest: 169+74.2% vs prev
Net Profit
₹ CrLatest: 42.0+244.8% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Bearish setupTrend is weak — long-term trend down. RSI 38.
- Price < SMA20 < SMA50 < SMA200 — full bearish stack.
- SMA20 falling (~4.5% over last month) — short-term momentum negative.
- RSI(14) at 38 — falling, no extreme reading.
- MACD below signal, histogram expanding negatively — bearish momentum building.
- 46% off 52W high · 11% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
14
RS percentile
Stage 4 Downtrend
1M return
-4.9%
3M return
-11.4%
6M return
-28.2%
1Y return
-44.0%
RS 1D
+3
RS 20D
+1
Sector rank
#1
Industry rank
#9
Stage evidence
- Price is 14.7% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -1.6%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
21 Oct 2026Value 55.38+0.95%
RS vs Nifty 50055
Valuation & peers
U-Score 51 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 51 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · FAIR VALUEValuation26/30
Growth20/25
Quality0/20
Balance Sheet3/15
Cash Flow1/10
Piotroski
6/9 (+3)
Penalties
-2
Raw sum
51
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
51/100 · legacy band FAIR VALUE
Positive drivers
- Fair-value margin of safety is positive at 74.0%.
- Valuation contributes 26/30 to the score.
- Growth contributes 20/25 to the score.
Main drags
- Altman Z is 1.7, in distress territory.
- Penalty bucket subtracts 2 points.
- Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
12.2
PB
0.4
EV/EBITDA
—
ROE
3.4%
ROCE
2.2%
FCF Yield
—
Debt/Equity
0.2
MoS
+74.0%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 21 Oct 2026
v4.3-runtime-valuation
Final score
51
Previous: 51
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+74.0%
Previous: +74.0%
Score history
12 stored score snapshots. Latest stored move: +0 points.
21 Oct 2026
v4.3-runtime-valuation
51
51
51
51
51
51
51
51
51
51
51
51
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹2.59
+54.7% MoS
Growth-justified P/E
45.0
Growth-justified Value
₹4.5
+74.0% MoS
PEG
0.25
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
ARVEE
Small
Arvee Laboratories (India) Limited
Pharmaceuticals
match 137
16
57.0
7.3%
-736%
OVERVALUED
BROOKS
Small
Brooks Laboratories Limited
Pharmaceuticals
match 136
60
12.1
22.0%
+68%
UNDERVALUED
AMBALALSA
Small
Ambalal Sarabhai Enterprises Limited
Pharmaceuticals
match 136
41
20.4
12.4%
+30%
WATCHLIST
BALPHARMA
Small
Bal Pharma Limited
Pharmaceuticals
match 135
23
23.6
7.9%
-44%
OVERVALUED
ALPA
Small
Alpa Laboratories Limited
Pharmaceuticals
match 134
32
30.6
8.4%
+40%
WATCHLIST
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Vikas Lifecare Limited operates in the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
44Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 2nd percentile of the scored universe and 2nd percentile within Pharma. Main check: financial discipline is weak at 22/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
1 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
2nd percentile
overall median 67 · Pharma: 2nd pctile, median 70 · Small: 2nd pctile, median 66
Evidence depth
Financial-only
1 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Do not rely on management narrative unless hard turnaround evidence is visible.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
66
acceptable · holding, pledge, alignment
Cash flow
43
weak · profit to cash conversion
Balance sheet
55
watch · leverage and solvency
Discipline
22
weak · capital discipline
Results
31
weak · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
Trust risks
- ▸Altman Z is 1.78.
- ▸3 latest quarters had PAT decline worse than 25% YoY.
- ▸Promoter holding is only 14.2%.
- ▸Only 1 years of positive FCF.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Vikas Lifecare Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
AnnouncementSep 2025
Sep 2025 · Announcement under Regulation 30 (LODR)-Newspaper Publication 25 Apr - Newspaper Advertisement of Un-Audited Financial Results of the Company for the Quarter ended September 30, 2025 and Quarter and Nine Months ended December 31, 2025
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.